Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...